Eli Lilly's oral obesity drug Foundayo has treated over 20,000 patients in its early launch. Novo Nordisk's oral Wegovy has captured 65% of new U.S. prescriptions in its first quarter. The rapid ...
Source LinkEli Lilly's oral obesity drug Foundayo has treated over 20,000 patients in its early launch. Novo Nordisk's oral Wegovy has captured 65% of new U.S. prescriptions in its first quarter. The rapid ...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.